Lichen-Derived Vitamin D3 Encyclopedia — Scientific Background

What Is Cholecalciferol?

Cholecalciferol (CAS 67-97-0), also known as vitamin D3, colecalciferol, or calciol, is a fat-soluble secosteroid with the molecular formula C₂₇H₄₄O and a molecular weight of 384.64 g/mol. It is chemically designated as (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol. Cholecalciferol occurs as white to almost white crystals or crystalline powder that is practically insoluble in water, freely soluble in ethanol (96%), and soluble in fatty oils. Cholecalciferol is the form of vitamin D that is naturally synthesized in the skin of humans and animals upon exposure to UVB radiation from sunlight, and it is also obtained through dietary intake from animal sources such as fatty fish and egg yolks.

The Lichen Source Advantage

The overwhelming majority of vitamin D3 (cholecalciferol) on the world market is produced from lanolin—the grease from sheep’s wool. That makes conventional D3 an animal-derived ingredient, which creates two significant problems for modern formulators: it cannot be labelled vegan, and it invites additional scrutiny in halal review because of its animal origin.

This product is derived from lichen—specifically Cladonia rangiferina (reindeer lichen), which is one of the richest natural sources of vitamin D. Lichen-derived vitamin D3 has the same molecular structure and conformation as cholecalciferol from animal sources, ensuring equivalent biological activity while meeting vegan, vegetarian, and halal dietary requirements. The production process involves a multistep process of extraction, purification, and concentration resulting in a vitamin D3 cholecalciferol with the same molecular structure and conformation as cholecalciferol from other sources.

Lichen-derived vitamin D3 has achieved FDA GRAS (Generally Recognized as Safe) status for use in dietary supplements and food fortification, providing a clear pathway for market entry. Additionally, most lichen-based vegan D3 has been on the market prior to 1997 and is not classified as novel under EU Novel Food Regulation (EU) 2015/2283, giving it a regulatory advantage in the European Union.

Physiological Functions of Vitamin D3

Vitamin D3 is critical for numerous physiological functions:

• Calcium and Phosphorus Homeostasis — Vitamin D3 promotes intestinal calcium absorption and renal calcium reabsorption, maintaining normal serum calcium and phosphorus levels essential for bone mineralization and neuromuscular function.

• Bone Health — Vitamin D3 supports bone mineralization and is essential for the prevention and treatment of rickets in children and osteomalacia in adults.

• Immune Function — Vitamin D3 modulates both innate and adaptive immune responses, supporting the body‘s natural defense mechanisms.

• Neuromuscular Function — Vitamin D3 contributes to normal muscle function and neuromuscular signaling.

• Cell Growth and Differentiation — Vitamin D3 regulates cell growth, differentiation, and apoptosis, supporting normal cellular function.

• Cardiometabolic Function — Mounting evidence supports broader roles for vitamin D3 in immune and cardiometabolic function.

Mechanisms of Action

Vitamin D Receptor (VDR) Signaling

Vitamin D3 is metabolized to 25-hydroxyvitamin D3 in the liver and then to the biologically active 1,25-dihydroxyvitamin D3 in the kidneys. The active metabolite binds to the vitamin D receptor (VDR), a nuclear receptor that regulates the transcription of target genes involved in calcium and phosphorus homeostasis, bone metabolism, immune function, and cell growth.

Calcium Absorption and Bone Mineralization

Vitamin D3 enhances intestinal calcium absorption by increasing the expression of calcium transport proteins, including TRPV6 and calbindin-D9k, in the intestinal epithelium. It also promotes renal calcium reabsorption and regulates parathyroid hormone (PTH) secretion, maintaining normal calcium homeostasis essential for bone mineralization.

Immune Modulation

Vitamin D3 modulates immune function by regulating the activity of immune cells, including T lymphocytes, macrophages, and dendritic cells. It enhances the antimicrobial activity of monocytes and macrophages and modulates cytokine production, supporting both innate and adaptive immune responses.

The Bioavailability Challenge

Despite its essential physiological functions, conventional oral cholecalciferol presents significant bioavailability challenges. As a highly lipophilic molecule, D3 is commonly dosed in oils or solid dosage forms that can be poorly palatable, slow to absorb, or unstable in aqueous settings. Stability studies show rapid degradation of D3 in water under light/oxygen and at unfavorable pH or ionic strengths. Additionally, cholecalciferol absorption is dependent on bile salt-mediated micelle formation and is influenced by dietary fat intake, leading to variability in bioavailability. Vitamin D3 deficiency is increasingly prevalent and linked to impaired health and disease, and while vitamin D3 supplementation is effective, variability in absorption can influence bioavailability and clinical responses.

These limitations have driven the development of advanced delivery systems, including liposomal encapsulation. Liposomal vitamin D3 causes a rapid increase in the plasma concentration of calcidiol, an effect that was especially pronounced for people with severe vitamin D3 deficiency.

Liposomal Lichen-Derived Vitamin D3

Liposomal encapsulation of cholecalciferol provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the cholecalciferol molecule, forming a protective shell that enhances stability, bioavailability, and cellular uptake. This delivery system:

• Achieves 1.9-fold higher AUC compared to non-liposomal formulations in a randomized double-blind crossover clinical study

• Achieves higher peak concentration (8.4 vs 6.0 ng/mL) and sustained elevation above baseline at 48 hours

• Demonstrates rapid absorption in deficiency states, especially pronounced for people with severe vitamin D3 deficiency

• Achieves encapsulation efficiencies approaching 99% — among the highest reported for liposomal vitamin D3 formulations

• Provides a 24-month shelf-life supported by accelerated stability studies

• Protects vitamin D3 from light, oxygen, and pH-induced degradation

Clinical Evidence

Enhanced Acute Absorption — Randomized Controlled Trial

A randomized, double-blind, crossover absorption study enrolled 12 healthy adults (mean age 34.3 ± 9.7 years; BMI 24.8 ± 2.7 kg/m²) to compare the absorption of a liposomal vitamin D3 formulation with a conventional non-liposomal formulation. Participants received a single oral dose of both formulations in random order separated by a 2-week washout period, and blood samples were collected over 48 hours post-dose. The liposomal formulation showed greater systemic absorption compared with the comparator formulation, with a 1.9-fold higher AUC (199 vs 106 ng·h/mL). Peak concentration was also higher for the liposomal formulation (8.4 vs 6.0 ng/mL). Circulating cholecalciferol concentrations remained elevated above baseline at 48 hours in the liposomal formulation but returned to baseline in the comparator formulation.

Rapid Absorption in Deficiency States

A clinical experiment compared liposomal vitamin D3 with an oily formulation. The results showed that liposomal vitamin D3 causes a rapid increase in the plasma concentration of calcidiol, while no such effect was observed when the oily formulation was used. The effect was especially pronounced for people with severe vitamin D3 deficiency. This was the first demonstration that absorption of vitamin D3 in liposomes depends on its status in the organism, with liposomal vitamin D3 absorbed faster by persons with distinct deficiency.

Bone Health — 24-Month Randomized Controlled Trial

A 24-month randomized controlled intervention in post-menopausal women (n = 153) evaluated liposomal vitamin D3 (800 IU/day + 1,000 mg calcium) compared with conventional formulations. Greater success in raising bone mineral density and lowering indicators of bone turnover was observed with bioavailability-enhanced vitamin D3 formulas in post-menopausal women.

Safety and Regulatory

Vitamin D3 has a well-established safety profile when used appropriately. The Tolerable Upper Intake Level (UL) for vitamin D is 4,000 IU/day for adults, although higher doses may be used under medical supervision. Excessive intake of vitamin D can cause hypercalcemia, which may result in nausea, vomiting, weakness, and renal complications.

Regulatory Status:

• United States — Cholecalciferol is regulated as a dietary supplement ingredient and food additive. Lichen-derived vitamin D3 has FDA GRAS (Generally Recognized as Safe) status for use in dietary supplements and food fortification, providing a clear pathway for market entry. It is monographed in the USP with an assay specification of 97.0%–103.0% on the anhydrous basis.

• European Union — Cholecalciferol is monographed in the European Pharmacopoeia (Ph. Eur. monograph 0072) and is authorized as a vitamin and mineral substance which may be used in the manufacture of food supplements. Most lichen-based vegan D3 has been on the market prior to 1997 and is not classified as novel under EU Novel Food Regulation (EU) 2015/2283, giving it a regulatory advantage. EU maximums vary by member state.

• Global Standards — Cholecalciferol is monographed in the USP, European Pharmacopoeia, British Pharmacopoeia, and Japanese Pharmacopoeia. It is available with Halal and Kosher certifications. The product complies with USP/EP/BP specifications including specific optical rotation (+105° to +112°), specific absorbance at 265 nm (460–490), and melting point (83–86°C).

Precautions: Cholecalciferol is generally well tolerated at recommended doses. Excessive intake of vitamin D can cause hypercalcemia, which may result in nausea, vomiting, weakness, and renal complications. Individuals with hypercalcemia, hyperphosphatemia, or severe renal impairment should consult a healthcare professional before use. Pregnant or lactating women and children should consult a healthcare professional before use. Cholecalciferol may interact with certain medications, including thiazide diuretics, cardiac glycosides, and corticosteroids.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, British Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

599$/KG

189$/KG